The study will compare the safety and efficacy of Bimatoprost and Latanoprost in patients with glaucoma or ocular hypertension

Study Type: Interventional

Study Design: Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study

Study Primary Completion Date: August 2008

Intervention(s) in this Clinical Trial

• Drug: bimatoprost 0.03% eye drops
  • Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of bimatoprost 0.03% 1 drop every evening for 12 weeks
• Drug: latanoprost 0.005% eye drops
  • Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of latanoprost 0.005% 1 drop every evening for 12 weeks

Arms, Groups and Cohorts in this Clinical Trial

• Active Comparator: 1
• Active Comparator: 2

Primary Measures

• IOP
  • Time Frame: Week 18
    Safety Issue?: No

Secondary Measures

• Adverse Events
  • Time Frame: Day 1 - Week 18
    Safety Issue?: No

Inclusion Criteria:

• Ocular hypertension or chronic glaucoma
• Patient requires IOP-lowering therapy in both eyes

Exclusion Criteria:

• Uncontrolled medical conditions
• Hypersensitivity to study medications

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: Allergan

Overall Clinical Trial Officials and Contacts

Medical Director Study Director Allergan  

Information obtained from ClinicalTrials.gov on August 28, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00541242

Study ID Number: 192024-034

ClinicalTrials.gov Identifier: NCT00541242

Health Authority: United States: Institutional Review Board